Form 4: Alnylam CEO Yvonne Greenstreet Reports Stock Transactions

Alnylam Pharmaceuticals' CEO, Yvonne Greenstreet, reports acquisition and disposal of company stock, including shares from vested performance-based stock units and sales to cover tax obligations.

Summary

• Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, reported transactions involving Alnylam common stock.
• On February 13, 2025, Greenstreet acquired 3,859 shares of common stock related to the vesting of a performance-based stock unit (PSU) granted in 2021.
• The vesting was based on Alnylam publicly reporting achievement of non-GAAP operating income profitability for a 12-month calendar year on or before December 31, 2025.
• From February 14, 2025, Greenstreet sold a total of 1,142 shares at prices ranging from $252.50 to $264.87 per share.
• These sales were automatically executed by the company to cover minimum statutory tax withholding obligations due upon the vesting of restricted stock units.
• Greenstreet also indirectly owns 407 shares through a managed account.
• Following these transactions, Greenstreet directly owns 81,526 shares and indirectly owns 407 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine, with the vesting of shares being a positive sign, but the subsequent sale to cover taxes is a standard practice and doesn't necessarily indicate a negative outlook.

Positives

• The vesting of the performance-based stock unit suggests that Alnylam is progressing towards achieving its financial goals, specifically non-GAAP operating income profitability.
• The CEO continues to hold a significant number of shares in the company, indicating confidence in its future prospects.

Negatives

• The sale of shares, even if for tax purposes, could be interpreted negatively by some investors, although it's a common practice.
• The vesting of the PSU is dependent on achieving a specific financial target by a certain date, introducing an element of uncertainty.

Risks

• Failure to achieve the non-GAAP operating income profitability target by December 31, 2025, would impact future vesting of performance-based stock units.
• Market fluctuations could affect the value of the shares held by the CEO and other investors.
• Unforeseen circumstances could impact Alnylam's ability to maintain its current financial trajectory.

Future Outlook

The vesting of future shares is contingent upon Alnylam achieving non-GAAP operating income profitability by December 31, 2025.

Industry Context

Stock transactions by company executives are common and closely monitored by investors as they can provide insights into management's perspective on the company's prospects. Sales to cover tax obligations are a normal part of equity compensation.

Comparison to Industry Standards

• Executive stock ownership and trading activities are standard practice across the pharmaceutical industry.
• Companies like Moderna, BioNTech, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.
• The size and frequency of these transactions are generally proportional to the executive's compensation and the company's market capitalization.
• Alnylam's executive compensation structure, including performance-based stock units, is similar to those used by its peers to incentivize performance and align management's interests with those of shareholders.

Stakeholder Impact

• The vesting of performance-based stock units aligns management's interests with shareholders by incentivizing the achievement of financial targets.
• The sale of shares to cover tax obligations has a minimal impact on stakeholders.

Key Dates

Keywords

Alnylam Pharmaceuticals, Yvonne Greenstreet, stock transactions, Form 4, CEO, performance-based stock unit, non-GAAP operating income, tax withholding, vesting